Detecting Alzheimer's disease biomarkers: From antibodies to new bio-mimetic receptors and their application to established and emerging bioanalytical platforms – A critical review

Scarano, Simona; Lisi, Samuele; Ravelet, Corinne; Peyrin, Eric; Minunni, Maria

doi:10.1016/j.aca.2016.08.008

Cited by 48 publications

(26 citation statements)

References 146 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the top research priorities in nanomedicine is the implementation of nanotechnology-based diagnostics tools able to identify disease as early as possible, ideally at the level of a single molecule biomarker 1 , 2 . Early detection of specific disease biomarkers and effective diagnosis are important for disease screening, preventing epidemics and enabling physicians to provide the right therapy 3 . Specifically, a large number of disease biomarkers are proteins and their presence in biological fluids are considered an indicator of the presence of some diseases such as diabetes, cancers and so on 4 .…”

Section: Introductionmentioning

confidence: 99%

Flexible and Tunable 3D Gold Nanocups Platform as Plasmonic Biosensor for Specific Dual LSPR-SERS Immuno-Detection

Focșan

Craciun

Potara

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Early medical diagnostic in nanomedicine requires the implementation of innovative nanosensors with highly sensitive, selective, and reliable biomarker detection abilities. In this paper, a dual Localized Surface Plasmon Resonance - Surface Enhanced Raman Scattering (LSPR- SERS) immunosensor based on a flexible three-dimensional (3D) gold (Au) nanocups platform has been implemented for the first time to operate as a relevant “proof-of-concept” for the specific detection of antigen-antibody binding events, using the human IgG - anti-human IgG recognition interaction as a model. Specifically, polydimethylsilane (PDMS) elastomer mold coated with a thin Au film employed for pattern replication of hexagonally close-packed monolayer of polystyrene nanospheres configuration has been employed as plasmonic nanoplatform to convey both SERS and LSPR readout signals, exhibiting both well-defined LSPR response and enhanced 3D electromagnetic field. Synergistic LSPR and SERS sensing use the same reproducible and large-area plasmonic nanoplatform providing complimentary information not only on the presence of anti-human IgG (by LSPR) but also to identify its specific molecular signature by SERS. The development of such smart flexible healthcare nanosensor platforms holds promise for mass production, opening thereby the doors for the next generation of portable point-of-care devices.

show abstract

Section: Introductionmentioning

confidence: 99%

Flexible and Tunable 3D Gold Nanocups Platform as Plasmonic Biosensor for Specific Dual LSPR-SERS Immuno-Detection

Focșan

Craciun

Potara

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Alzheimer’s disease (AD) is the most common form of dementia in elderly individuals and, at the present, it is one of the major challenges of the global public health [ 1 ]. However, the pathogenic complexity of the disease together with some clinical signs, common to other neurodegenerative diseases (e.g., elderly dementia, fronto-temporal dementia) [ 1 , 2 , 3 , 4 , 5 , 6 ], make the diagnosis and the development of effective treatments for AD difficult.…”

Section: Introductionmentioning

confidence: 99%

A Comparison of Lysosomal Enzymes Expression Levels in Peripheral Blood of Mild- and Severe-Alzheimer’s Disease and MCI Patients: Implications for Regenerative Medicine Approaches

Morena

Argentati

Trotta

et al. 2017

IJMS

View full text Add to dashboard Cite

The association of lysosomal dysfunction and neurodegeneration has been documented in several neurodegenerative diseases, including Alzheimer’s Disease (AD). Herein, we investigate the association of lysosomal enzymes with AD at different stages of progression of the disease (mild and severe) or with mild cognitive impairment (MCI). We conducted a screening of two classes of lysosomal enzymes: glycohydrolases (β-Hexosaminidase, β-Galctosidase, β-Galactosylcerebrosidase, β-Glucuronidase) and proteases (Cathepsins S, D, B, L) in peripheral blood samples (blood plasma and PBMCs) from mild AD, severe AD, MCI and healthy control subjects. We confirmed the lysosomal dysfunction in severe AD patients and added new findings enhancing the association of abnormal levels of specific lysosomal enzymes with the mild AD or severe AD, and highlighting the difference of AD from MCI. Herein, we showed for the first time the specific alteration of β-Galctosidase (Gal), β-Galactosylcerebrosidase (GALC) in MCI patients. It is notable that in above peripheral biological samples the lysosomes are more sensitive to AD cellular metabolic alteration when compared to levels of Aβ-peptide or Tau proteins, similar in both AD groups analyzed. Collectively, our findings support the role of lysosomal enzymes as potential peripheral molecules that vary with the progression of AD, and make them useful for monitoring regenerative medicine approaches for AD.

show abstract

“…Alzheimer’s disease (AD), the most common neurodegenerative disease, is defined by short-term memory loss progressing into dementia and neuropathology [ 1 – 3 ]. It has been estimated that 46 million people are affected by dementia syndromes in 2015 and about 60~70% of them are diagnosed as AD [ 4 ]. The hippocampus and the surrounding cortical regions are the major sites of AD-related pathology [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

ATP Binding Cassette Subfamily A Member 2 (ABCA2) Expression and Methylation are Associated with Alzheimer’s Disease

Lin

Zhang

et al. 2017

Med Sci Monit

View full text Add to dashboard Cite

BackgroundABCA2 has been genetically linked to Alzheimer’s disease (AD) risk, but its mRNA expression and epigenetics in AD have not been investigated.Material/MethodTo explore the diagnosis value of ABCA2 mRNA expression in AD, 2 datasets GES15222 and GSE33000 containing expression profile of brain cortex tissues and 2 datasets GSE63063 (Cohort 1) and GSE63063 (Cohort 2) containing expression profile of blood were downloaded from the NCBI GEO database and analyzed by receiver operating characteristic curve (ROC) analyses and logistic regression. The ABCA2 co-expressed genes were also analyzed by GO annotation to investigate the potential molecular mechanisms.ResultsThe analyses results suggested ABCA2 mRNA expression was upregulated significantly in AD compared with controls in all datasets. ROC analysis suggested that ABCA2 was associated with AD in all datasets, which were also proved by univariate and multivariate analyses. Next, the dataset GSE80970 containing methylation profiles of prefrontal cortex tissues from AD patients were downloaded and analyzed. Methylation of 2 of 36 CpG islands in ABCA2 gene with high diagnostic accuracy of AD from controls in ROC analyses were found to be negatively associated with AD risk in univariate analysis. One was still associated with AD risk after adjustment of confounding factors. Additional analyses indicated that ACBA2 mRNA expression could be used to diagnose mild cognitive impairment (MCI) and Huntington’s disease (HD) from controls and to distinguish HD from AD, but not AD from MCI. Furthermore, the genes involved in AD during ABCA2 alteration were analyzed by GO analysis.ConclusionsABCA2 mRNA expression and methylation is associated AD risk. ABCA2 may be used as a biomarker for AD diagnosis and may be a potential therapeutic target of AD.

show abstract

Detecting Alzheimer's disease biomarkers: From antibodies to new bio-mimetic receptors and their application to established and emerging bioanalytical platforms – A critical review

Cited by 48 publications

References 146 publications

Flexible and Tunable 3D Gold Nanocups Platform as Plasmonic Biosensor for Specific Dual LSPR-SERS Immuno-Detection

Flexible and Tunable 3D Gold Nanocups Platform as Plasmonic Biosensor for Specific Dual LSPR-SERS Immuno-Detection

A Comparison of Lysosomal Enzymes Expression Levels in Peripheral Blood of Mild- and Severe-Alzheimer’s Disease and MCI Patients: Implications for Regenerative Medicine Approaches

ATP Binding Cassette Subfamily A Member 2 (ABCA2) Expression and Methylation are Associated with Alzheimer’s Disease

Contact Info

Product

Resources

About